NGNE

NeurogeneB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$42.00

+60.7% vs current

Most likely

Base case

45%

Probability

Target price

$24.00

-8.2% vs current

B-

Bear case

30%

Probability

Target price

$9.00

-65.6% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is cautiously constructive but still monitoring-oriented. Primary company sources support real progress in Rett syndrome, especially Breakthrough Therapy designation, full enrollment in Embolden, and cash runway through the first quarter of 2028, which provides a longer-horizon financing and execution bridge alongside the mid-2026 data event [#IR-2026-02-26][#IR-2026-03-24][#10-K-2026-03-24]. Even so, deterministic signals are near-neutral and the stock still trades as a high-volatility clinical event story rather than a de-risked commercialization case.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystEmbolden dosing completion targeted for Q2 2026High impact

Neurogene said 100% of participants are enrolled in the Embolden registrational trial, more than half have been dosed, and the company remains on track to complete dosing in the second quarter of 2026, making execution against that timeline the clearest near-term stock driver [#IR-2026-03-24][#8-K-2026-03-24].

2026-07-15eventMid-2026 interim Phase 1/2 updateHigh impact

Management guided to updated interim safety and efficacy data in mid-2026 covering the pediatric and adolescent/adult cohorts, including at least 12 months of follow-up for all 10 participants; for a single-asset Rett story, this readout is likely the main valuation event [#IR-2026-03-24][#IR-2026-01-12].

2027-03-31catalystRunway-backed PPQ and filing-readiness path into 2027High impact

Neurogene said PPQ is planned to begin in mid-2026, commercial manufacturing scale matches clinical scale, and cash, cash equivalents and short-term investments of $269.0 million at December 31, 2025 are expected to fund operations through the first quarter of 2028; that gives the company a distinct financing and execution bridge to pursue manufacturing validation and later filing-readiness milestones without an immediate capital raise [#IR-2026-03-24][#10-K-2026-03-24].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology